Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STONE-001: Radiotherapy + PD-L1 Inhibitor Maintenance in ES-SCLC
NCT06719336Phase 3Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2028
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) (2 arms). Primary endpoint: Overall Survival at 4 years. Planned start Dec 2024; status: not yet recruiting.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06719336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719336.